Active Ingredient(s): Mogamulizumab-kpkc
FDA Approved: * August 8, 2018
Pharm Company: * KYOWA KIRIN
Category: Cancer

Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4).[3] The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease.[4] It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refracto... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Poteligeo 4 mg/ml Intravenous Injection
NDC: 42747-761
Kyowa Kirin, Inc.